2 hours Travere Therapeutics (NASDAQ:TVTX) PT Lowered to $22.00 MarketBeat
Canaccord Genuity Group lowered their price target on Travere Therapeutics from $23.00 to $22.00 and set a “buy” rating for the company in a report on Monday.
Canaccord Genuity Group lowered their price target on Travere Therapeutics from $23.00 to $22.00 and set a “buy” rating for the company in a report on Monday.